Revefenacin
Revefenacin.svg
Clinical data
Trade namesYupelri
AHFS/Drugs.comMonograph
MedlinePlusa619009
License data
Routes of
administration
Inhalation
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC35H43N5O4
Molar mass597.760 g·mol−1
3D model (JSmol)
  • CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
  • InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
  • Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]

References

  1. ^ "Theravance Biopharma and Mylan Receive FDA Approval for Yupelri (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. 9 November 2018. Archived from the original on 15 September 2019. Retrieved 17 January 2019.
  2. ^ Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.
  3. ^ Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD (May 2020). "Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis". BMC Pulmonary Medicine. 20 (1): 134. doi:10.1186/s12890-020-1156-4. PMC 7216337. PMID 32393215.